| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
STERIS plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$230.60 |
| 52 Week High | US$254.00 |
| 52 Week Low | US$195.47 |
| Beta | 0.81 |
| 1 Month Change | 14.78% |
| 3 Month Change | -2.30% |
| 1 Year Change | 14.82% |
| 3 Year Change | 18.76% |
| 5 Year Change | 72.85% |
| Change since IPO | 11,080.61% |
Recent News & Updates
Recent updates
Steris: Moving On, Losing Its Teeth
Apr 14STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price
Mar 29
STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Mar 07Steris: Strong Healthcare Products Growth Coupled With Weak AST Business
Feb 17STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't
Feb 15An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued
Dec 17Should You Investigate STERIS plc (NYSE:STE) At US$203?
Nov 24Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes
Nov 08We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt
Nov 06Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?
Sep 18Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage
Sep 01When Should You Buy STERIS plc (NYSE:STE)?
Aug 10Steris: Continuing To Grow The Product Lineup
Jun 20Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered
Feb 09Steris declares $0.47 dividend
Feb 01These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well
Feb 01Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)
Dec 28Steris declares $0.47 dividend
Nov 02STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly
Nov 01Steris: Non-GAAP Valuations Supportive Of Substantial Upside
Sep 04STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47
Aug 18STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47
Aug 04Steris Non-GAAP EPS of $1.90 in-line, revenue of $1.2B misses by $20M
Aug 02Is STERIS (NYSE:STE) A Risky Investment?
Jul 19Steris: Deleveraging Key Undercurrent, Valuation A Concern
Jun 12STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly
Apr 08Steris: Another Essential Healthcare Supply Resource
Feb 01Shareholder Returns
| STE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.1% | -0.2% | -0.2% |
| 1Y | 14.8% | 5.2% | 28.2% |
Return vs Industry: STE exceeded the US Medical Equipment industry which returned 4.2% over the past year.
Return vs Market: STE underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| STE volatility | |
|---|---|
| STE Average Weekly Movement | 3.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: STE has not had significant price volatility in the past 3 months.
Volatility Over Time: STE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 17,000 | Dan Carestio | www.steris.com |
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
STERIS plc Fundamentals Summary
| STE fundamental statistics | |
|---|---|
| Market cap | US$22.79b |
| Earnings (TTM) | US$551.44m |
| Revenue (TTM) | US$5.14b |
41.3x
P/E Ratio4.4x
P/S RatioIs STE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STE income statement (TTM) | |
|---|---|
| Revenue | US$5.14b |
| Cost of Revenue | US$2.89b |
| Gross Profit | US$2.25b |
| Other Expenses | US$1.70b |
| Earnings | US$551.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.58 |
| Gross Margin | 43.72% |
| Net Profit Margin | 10.73% |
| Debt/Equity Ratio | 49.4% |
How did STE perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield36%
Payout RatioDoes STE pay a reliable dividends?
See STE dividend history and benchmarks| STERIS dividend dates | |
|---|---|
| Ex Dividend Date | Jun 12 2024 |
| Dividend Pay Date | Jun 26 2024 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 33 days |
Does STE pay a reliable dividends?
See STE dividend history and benchmarks